MedTrace Logo

Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry

NCT06086132 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2025-06-19

No results posted yet for this study

Summary

This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction

Conditions

  • Cancer Related Cardiovascular Toxicity

Interventions

COMBINATION_PRODUCT

Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy

Follow-up visits at baseline, 3-months, and 1-year

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

    collaborator OTHER

  • University of Bologna

    lead OTHER

Principal Investigators

  • Prof. Olivia Manfrini, MD · University of Bologna

  • Prof. Giuseppina Novo, MD · Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Italy
  • North Macedonia
  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086132 on ClinicalTrials.gov